Author:
Barbhaiya Medha,Erkan Doruk
Publisher
Springer Science and Business Media LLC
Reference77 articles.
1. Miyakis S, Lockshin MD, Atsumi T, et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4:295–306.
2. • Erkan D, Lockshin MD: New approaches for managing antiphospholipid syndrome. Nature 2009, 5:160–170. This is a review article of the current management strategies for persistently aPL-positive patients. It discusses some of the potential new immunomodulatory approaches.
3. Vila P, Hernandez MC, Lopez-Fernandez MF, et al: Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. J Thromb Haemost. 1994, 72:209–213.
4. Galli M, Luciani D, Bertolini G, et al.: Lupus anticoagulants are stronger risk factors for thrombosis than anticoardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827–1832.
5. Pengo V, Ruffatti A, Legnani C, et al.: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010, 8:237–242.
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献